Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor suppression by Ink4a-Arf: progress and puzzles.

Scott W Lowe1, Charles J Sherr

  • 1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA. lowe@cshl.org

Current Opinion in Genetics & Development
|February 8, 2003
PubMed
Summary

The Ink4a-Arf locus produces tumor suppressors p16(Ink4a) and p19(Arf) (p14(ARF) in humans) that are crucial in cancer. Mouse models reveal distinct roles for these proteins in tumor development and drug response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gregory J. Hannon (1964-2026).

Cell·2026
Same author

GATA4 loss promotes mutant <i>Kras</i>-driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions.

bioRxiv : the preprint server for biology·2026
Same author

Hallmarks of liver cancer: Therapeutic implications.

Cell·2026
Same author

Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition.

Cell·2026
Same author

Senescence in cancer: Hallmarks, paradoxes, and therapeutic promise.

Cell·2026
Same author

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.

Cell·2026

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • The Ink4a-Arf locus encodes two key tumor suppressors: p16(Ink4a) and p19(Arf) (p14(ARF) in humans).
  • These proteins regulate critical cell cycle regulators, including the retinoblastoma protein and p53.
  • Their signaling network is frequently dysregulated in various cancer types.

Purpose of the Study:

  • To elucidate the distinct roles of p16(Ink4a) and p19(Arf) in tumor suppression.
  • To investigate the differential responsiveness of these tumor suppressors to therapeutic agents.

Main Methods:

  • Utilized mouse tumor models to study Ink4a-Arf locus products.
  • Differentiated the functional activities of p16(Ink4a) and p19(Arf) in tumor onset.
  • Assessed drug sensitivity associated with p16(Ink4a) and p19(Arf) activities.

Related Experiment Videos

Main Results:

  • Mouse models demonstrated that p16(Ink4a) and p19(Arf) have separate functions in regulating tumor initiation.
  • Differences in drug responsiveness were observed between p16(Ink4a) and p19(Arf) pathways.
  • The Ink4a-Arf locus responds to cellular stress, impacting proliferation and apoptosis.

Conclusions:

  • p16(Ink4a) and p19(Arf) possess distinct tumor suppressor activities.
  • Targeting these pathways may offer differential therapeutic strategies in cancer treatment.
  • Understanding the Ink4a-Arf network is vital for cancer therapy development.